| Michell Marola Lozano Chinga, MD | |
|
100 N Mario Capecchi Dr, Salt Lake City, UT 84113-1103 | |
| (801) 662-4700 | |
| Not Available |
| Full Name | Michell Marola Lozano Chinga |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 100 N Mario Capecchi Dr, Salt Lake City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467803726 | NPI | - | NPPES |
| Entity Name | Phoenix Children's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922112044 PECOS PAC ID: 0446278584 Enrollment ID: O20051107000704 |
News Archive
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michell Marola Lozano Chinga, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-8133 | Michell Marola Lozano Chinga, MD 100 N Mario Capecchi Dr, Salt Lake City, UT 84113-1103 Ph: (801) 662-4700 |
News Archive
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.
For up-to-date information about lung cancer, you can contact the Thomas G. Labrecque Foundation. The foundation was founded in 2002 by the Labrecque family in honor of Tom Labrecque, former chairman of the Chase Manhattan Bank. Mr. Labrecque, a non-smoker, died of lung cancer.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 9 days ago
Kristina Mckinley, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: University Of Utah Hospital, 30 North 1900 East, Rm 1c412, Salt Lake City, UT 84132 Phone: 801-581-2401 | |
Kaitlin Carpenter, Pediatrics Medicare: Medicare Enrolled Practice Location: 100 Mario Capecchi Dr, Salt Lake City, UT 84113 Phone: 801-662-1000 | |
Dr. Thomas Patrick Curtin, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 81 N Mario Capecchi Dr, Salt Lake City, UT 84113 Phone: 801-662-5700 | |
Anastasiya Mankouski, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5121 S Cottonwood St, Salt Lake City, UT 84107 Phone: 801-507-7000 | |
Joslynn Marie Hoburg, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 295 S Chipeta Way Rm 2s010, Salt Lake City, UT 84108 Phone: 801-581-2121 | |
George W Delavan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 44 N Mario Capecchi Dr, Salt Lake City, UT 84132 Phone: 801-584-8239 Fax: 801-584-8588 | |
Michelle Ploutz, Pediatrics Medicare: Medicare Enrolled Practice Location: 100 N Mario Capecchi Dr, Salt Lake City, UT 84113 Phone: 801-662-1000 Fax: 018-213-7778 |